DK3426250T3 - Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor - Google Patents

Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor Download PDF

Info

Publication number
DK3426250T3
DK3426250T3 DK17897227.9T DK17897227T DK3426250T3 DK 3426250 T3 DK3426250 T3 DK 3426250T3 DK 17897227 T DK17897227 T DK 17897227T DK 3426250 T3 DK3426250 T3 DK 3426250T3
Authority
DK
Denmark
Prior art keywords
cyp3a4
substrated
contraindicated
administration
patient
Prior art date
Application number
DK17897227.9T
Other languages
Danish (da)
English (en)
Inventor
Sundar Srinivasan
Christina Chow
Original Assignee
Bow River LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bow River LLC filed Critical Bow River LLC
Application granted granted Critical
Publication of DK3426250T3 publication Critical patent/DK3426250T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK17897227.9T 2017-05-16 2017-05-16 Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor DK3426250T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/596,585 US10376507B2 (en) 2017-05-16 2017-05-16 Method of treating a patient with a CYP3A4 substrate drug
PCT/US2017/032924 WO2018212764A1 (en) 2017-05-16 2017-05-16 Methods of treatment

Publications (1)

Publication Number Publication Date
DK3426250T3 true DK3426250T3 (da) 2022-05-16

Family

ID=64269934

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17897227.9T DK3426250T3 (da) 2017-05-16 2017-05-16 Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor
DK18926463.3T DK3716976T3 (da) 2017-05-16 2018-11-14 Fremgangsmåder til behandling med cyp3a4-substratlægemidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18926463.3T DK3716976T3 (da) 2017-05-16 2018-11-14 Fremgangsmåder til behandling med cyp3a4-substratlægemidler

Country Status (15)

Country Link
US (6) US10376507B2 (enExample)
EP (4) EP4082546A1 (enExample)
JP (7) JP2020520380A (enExample)
KR (3) KR20210010663A (enExample)
AU (10) AU2017414697B2 (enExample)
CA (1) CA3103793A1 (enExample)
DK (2) DK3426250T3 (enExample)
ES (2) ES2912373T3 (enExample)
FI (1) FI3716976T3 (enExample)
HR (1) HRP20220536T1 (enExample)
MX (4) MX2019013714A (enExample)
PL (1) PL3426250T3 (enExample)
SI (1) SI3426250T1 (enExample)
WO (2) WO2018212764A1 (enExample)
ZA (1) ZA202006746B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
JP7199359B2 (ja) * 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP2020520380A (ja) 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
US11110098B2 (en) * 2017-06-07 2021-09-07 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN109966298A (zh) * 2019-05-10 2019-07-05 辽宁大学 托伐普坦在制备降血脂药物中的应用
US20220233542A1 (en) * 2019-06-05 2022-07-28 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021071678A1 (en) * 2019-10-07 2021-04-15 University Hospitals Cleveland Medical Center Methods for treating wild type isocitrate dehydrogenase 1 cancers
JP7385300B2 (ja) * 2019-11-15 2023-11-22 株式会社カルディオインテリジェンス 医薬品の用法及び用量の少なくとも一方の決定を支援するための方法、プログラム、装置及びシステム
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CA3212191A1 (en) * 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
US20230293534A1 (en) * 2020-07-24 2023-09-21 Secura Bio, Inc. Treatment of cancers using pi3 kinase isoform modulators
KR102601028B1 (ko) 2020-08-18 2023-11-10 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
WO2022039421A1 (ko) * 2020-08-18 2022-02-24 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN111920814B (zh) * 2020-09-04 2022-02-11 郑州大学 依匹哌唑在制备抗肿瘤药物中的应用
CN112898131B (zh) * 2020-11-05 2023-08-22 苏州凯祥生物科技有限公司 大麻二酚的提取工艺及大麻二酚或大麻提取物在制备预防或者治疗bph的药物中的应用
CN112206297B (zh) * 2020-11-16 2022-01-11 深圳市宝安区人民医院 治疗心脾两虚型失眠症的中药制剂及其制备方法
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CA3201123A1 (en) * 2020-12-31 2022-07-07 Sundar Srinivasan Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN112675175B (zh) * 2021-02-01 2022-11-01 天津济坤医药科技有限公司 布里格替尼在制备治疗特发性肺纤维化的药物中的应用
WO2023101441A1 (ko) * 2021-11-30 2023-06-08 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
WO2023141634A2 (en) * 2022-01-24 2023-07-27 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US20250302821A1 (en) * 2022-05-12 2025-10-02 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method
CN117045643A (zh) * 2023-09-26 2023-11-14 江苏百奥信康医药科技有限公司 一种cftr矫正剂在制备治疗乳腺增生症的药物中的应用
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973970B2 (en) * 2000-08-09 2011-07-05 Ether Visuals Llc Preventing artifacts that may be produced when bottling PDL files converted from raster images
EP2023923A2 (en) * 2006-05-25 2009-02-18 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
AR102780A1 (es) * 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
KR20190067918A (ko) 2016-11-09 2019-06-17 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
JP2020520380A (ja) 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Also Published As

Publication number Publication date
KR20210045400A (ko) 2021-04-26
KR102805232B1 (ko) 2025-05-13
AU2018432858A1 (en) 2021-01-07
JP6984024B2 (ja) 2021-12-17
JP2021059610A (ja) 2021-04-15
AU2022204806A1 (en) 2022-11-10
EP3426250A4 (en) 2020-05-06
AU2020203608B2 (en) 2020-07-09
WO2020018136A1 (en) 2020-01-23
EP3426250A1 (en) 2019-01-16
JP2020520380A (ja) 2020-07-09
CA3062770A1 (en) 2018-11-22
US20190076425A1 (en) 2019-03-14
AU2020202100A1 (en) 2020-04-09
US11123346B2 (en) 2021-09-21
US20180333409A1 (en) 2018-11-22
AU2020202266A1 (en) 2020-04-23
PL3426250T3 (pl) 2022-08-08
KR20210010663A (ko) 2021-01-27
AU2020202100B2 (en) 2020-07-02
AU2020250281B2 (en) 2022-07-28
AU2017414697A1 (en) 2019-11-07
AU2020203607A1 (en) 2020-06-25
MX2021000609A (es) 2021-06-23
MX2025000380A (es) 2025-02-10
JP2023021260A (ja) 2023-02-10
AU2020203606A1 (en) 2020-06-25
ZA202006746B (en) 2023-03-29
KR20200010320A (ko) 2020-01-30
AU2020203606B2 (en) 2020-07-09
AU2020203608A1 (en) 2020-06-25
US10376507B2 (en) 2019-08-13
US20210154189A1 (en) 2021-05-27
AU2022204806B2 (en) 2025-04-24
EP3716976B1 (en) 2024-08-07
DK3716976T3 (da) 2024-10-28
EP4461298A3 (en) 2025-01-22
ES2912373T3 (es) 2022-05-25
FI3716976T3 (fi) 2024-10-25
AU2020202266B2 (en) 2020-05-14
AU2020203607B2 (en) 2020-07-09
EP3426250B1 (en) 2022-03-23
HRP20220536T1 (hr) 2022-06-10
JP2025137510A (ja) 2025-09-19
JP2023174661A (ja) 2023-12-08
US20180333411A1 (en) 2018-11-22
AU2022228153B2 (en) 2025-04-24
EP3716976A1 (en) 2020-10-07
JP2021510681A (ja) 2021-04-30
ES2993832T3 (en) 2025-01-10
JP2022022264A (ja) 2022-02-03
MX2019013714A (es) 2020-07-14
MX2022013410A (es) 2022-11-14
AU2018432858B2 (en) 2025-10-09
CA3103793A1 (en) 2020-01-23
EP4461298A2 (en) 2024-11-13
EP4082546A1 (en) 2022-11-02
US10835529B2 (en) 2020-11-17
AU2022228153A1 (en) 2022-09-29
JP7353343B2 (ja) 2023-09-29
AU2017414697B2 (en) 2020-03-05
EP3716976A4 (en) 2021-02-17
SI3426250T1 (sl) 2022-09-30
JP7698009B2 (ja) 2025-06-24
WO2018212764A1 (en) 2018-11-22
US20180333410A1 (en) 2018-11-22
AU2020250281A1 (en) 2020-11-05
US20190255043A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
DK3426250T3 (da) Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor
DK3717471T3 (da) Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme
PT3985002T (pt) Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
SI3455258T1 (sl) Postopki za zdravljenje kožnega raka z dajanjem zaviralca PD-1
TW201613911A (en) Heterocyclic compounds and uses thereof
MX380276B (es) Inhibidor jak.
DK3378482T3 (da) Formulering til administration af antitumorlægemiddel
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
MX381994B (es) Inhibidor de janus quinasa.
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
IL263516B (en) A dosage form for vaporization and smoking
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3193978T3 (da) Lægemiddelinjektor af hudplastertypen til voluminøs bolus med medikamentforvarmning
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
DK3256133T3 (da) Intravenøs infusionsdoseringsform
DK3326637T3 (da) Anvendelse af mangostanskalekstrakt til fremstilling af en medicin til behandling af hudlidelser
MX379245B (es) Compuesto de tres ciclos y aplicaciones del mismo
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
EP3528860C0 (en) CELL-ASSOCIATED SCAFFOLDS FOR AGENT DELIVERY
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet